<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460629</url>
  </required_header>
  <id_info>
    <org_study_id>EK126092000</org_study_id>
    <nct_id>NCT00460629</nct_id>
  </id_info>
  <brief_title>Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation</brief_title>
  <official_title>Specific Cellular Immunotherapy in Patients With Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Carl Gustav Carus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efforts to decrease the risk of GvHD by depleting T cells from the graft in CML patients have&#xD;
      been complicated by an increased incidence of leukemia-relapse. Newer protocols using CD34+&#xD;
      selected hematopoietic cells from matched-sibling donors and subsequent infusion of T cells&#xD;
      in incremental doses to treat or avoid relapse of disease seem to be more promising. In this&#xD;
      study, we try to further optimize this approach by the prophylactic infusion of cytotoxic T&#xD;
      cells activated ex-vivo against leukemia-associated/specific antigens using peptide-pulsed&#xD;
      dendritic cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The conditioning protocol contains:&#xD;
&#xD;
      Total Body Irradiation 8-12 Gy (4-6 x 2 Gy, a 2 x/die) day -9 to-7 Thiotepa 10 mg/kg (2 x 5&#xD;
      mg/kg) day -5 Fludarabine 200 mg/m2 (5 x 40 mg/m2) day -6 to-2 ATG Fresenius 25 mg/kg (5 x 5&#xD;
      mg/kg) day -6 to-2 Cyclosporine A 1 mg/kg Day -10 to-3&#xD;
&#xD;
      on day 0 CD34+ cells after immunomagnetic selection are infused. &gt; 4 x 10e6/kg CD34 cells/kg&#xD;
      are required.&#xD;
&#xD;
      On days 28, 56 and 112 after transplantation, cytotoxic T cells generated in-vitro are&#xD;
      infused in patients who do not have signs of acute GvHD.&#xD;
&#xD;
      Regular follow-up compromises immune monitoring including Tetramer analyses of&#xD;
      Peptide-reactive T cells&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of the infusion of in-vitro activated donor T cells</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>kinetic of BCR-ABL load after transplantation</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of acute and chronic GvHD</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infectious complications</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Application of activated donor T cells</intervention_name>
    <description>Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-60&#xD;
&#xD;
          -  Ph+ CML&#xD;
&#xD;
          -  HLA A0201, 0301, 1101, B0801&#xD;
&#xD;
          -  BCR-ABL b3a2 positive&#xD;
&#xD;
          -  no significant comorbidities&#xD;
&#xD;
          -  resistance or intolerance of imatinib&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  blast crisis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Bornh√§user, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Clinic, University Hospital Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Bornhauser M, Thiede C, Babatz J, Schetelig J, Illmer T, Kiani A, Platzbecker U, Herr W, Rieber EP, Ehninger G, Schmitz M. Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation. Leukemia. 2006 Nov;20(11):2055-7. doi: 10.1038/sj.leu.2404383. Epub 2006 Aug 31. No abstract available.</citation>
    <PMID>16990776</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2007</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adoptive immunotherapy</keyword>
  <keyword>BCR-ABL reactive T cells</keyword>
  <keyword>Allogeneic Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

